Provided herein are methods and compositions for sensitizing a cancer cell to a cancer treatment, for example to an anticancer drug by the inhibition of at least two cancer biomarkers. Further provided are methods of treating and/or preventing a cancer including reducing the size of a tumor. Also provided are compositions comprising nanopartides associated with inhibitory molecules, such as siRNA, and/or anti-cancer drugs.

The present disclosure relates to a multi-functional nanoparticle targeted to breast cancer, a preparation method and use thereof. The multi-functional nanoparticle includes a targeting carrier and a medicament loaded on the targeting carrier; and the targeting carrier is made from recombinant ferritin. Cell experiments verify that the multi-functional nanoparticle has better efficacy and drug release capacity for cancer cells than those of conventional ferritin as a vector. Moreover, the drug delivery system can further achieve optical imaging of tumor cells by loading quantum dots, thus playing a role in cancer diagnosis and treatment.

The present disclosure provides a compositions and methods of inhibiting O.sup.6-methylguanine DNA methyltransferase in human tumor cells by providing an effective amount of an agent that directly or indirectly inhibits the O.sup.6-methylguanine DNA methyltransferase in a pharmaceutically acceptable carrier, wherein the amount is effective to potentiate an anti-tumor activity of one or more alkylating agents, platinum drugs, or antimetabolites, wherein tumor cells are triggered into programmed cell death.

The invention provides solid lipid nanoparticles (SLNs) which comprise gold, and are useful as vectors for the transfection of different types of nucleic acids. Different methods for obtaining such SLNs are also disclosed.

For applications in drug delivery, “smart” materials have been designed to respond to conditions within microenvironments of tissues or cells. The present invention features stimuli-responsive cross-linked hydrogels that respond to specific metabolites of disease. For example, protein-polymer materials of the present invention are configured to release their drug cargo upon encountering the higher lactate concentrations within tumor microenvironments.

This disclosure provides systems, methods, and apparatus related to graphene. In one aspect, a method includes submerging a frame support in an etching solution that is contained in a container. A growth substrate, a graphene sheet disposed on the growth substrate, and a primary support disposed on the graphene sheet is placed on a surface of the etching solution. The growth substrate is dissolved in the etching solution to leave the graphene sheet and the primary support floating on a surface of the etching solution. The etching solution in the container is replaced with a washing solution. The washing solution is removed from the container so that the graphene sheet becomes disposed on the frame support.

A multidimensional nanoconstruct includes a three-dimensional thiolated protein, gelatin or polymer nanoparticle and exposed metallic nanoparticles bonded to outer surfaces of the particle. In a method of formation, number of metallic nanoparticles that attach to the carrier nanoparticle is controlled via microfluidics or via controlling the reactivity of the metallic nanoparticle and carrier nanoparticle.

Disclosed are a self-assembled catalase nanoparticle and a preparation method therefor and the use thereof. The self-assembled catalase nanoparticle of the present invention is obtained by dissolving catalase freeze-dried powder to obtain a catalase solution, adjusting the pH value of the catalase solution, and then centrifugating or filtering same to obtain a supernatant or a filtrate, and further thermally incubating the supernatant or filtrate. The self-assembling catalase nanoparticle of the present invention can be used in medicines or food products that promote immune cell growth and regulate organic immunity.

The present disclosure provides nanoparticles comprising methyl palmitate and at least one serumglobular protein and uses thereof.

The present application provides methods and compositions for treating cancer by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and a carrier protein (such as an albumin) based upon the mutation status of TSC1 or TSC2 and one of VHL, RBI, PBRIM1, K.DM6A, RET, SETD2 ARID 1 A, BAP1, BRCA2, TP53, RBI, ATRX, FLT1, NTRK1, TLX3, KDM6A, CDH4, CDKN2C, DAXX, ERBB3, GNAS, IL7R, PDGFRB, PMS2, PTEN, SMARCA4, and YY1AP1.